AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20415801 — intervention group
Group type: COMPARATOR
Intervention: Xylitol chewing gum (two xylitol gum pellets for at least 5 minutes three times daily, dose: 4.3g/day)
Number of subjects: 105
Study 20415801 — intervention group
Group type: COMPARATOR
Intervention: Negative control (used neither product)
Number of subjects: 105
Study 18710748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist therapy (2, 6-month cycles)
Number of subjects: 0
Study 18710748 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide treatment
Number of subjects: 0
Study 18710748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline dihydroxytestosterone and age over 67 years
Number of subjects: 0
Study 18710748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior local radiation therapy
Number of subjects: 0
Study 18710748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline dihydroxytestosterone and testosterone, low testosterone nadir, and white race
Number of subjects: 0
Study 15933273 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-environment (P-E) fit problems
Number of subjects: 72
Study 15933273 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADLs) dependence
Number of subjects: 72
Study 15933273 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional limitations and dependence on mobility devices
Number of subjects: 72
Study 15933273 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental barriers
Number of subjects: 72
Study 11375230 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage during the second stage of labour with a water soluble lubricant
Number of subjects: 1340
Study 11375230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perineal massage)
Number of subjects: 1340
Study 11398305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray 1 mg
Number of subjects: 52
Study 11398305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray 0.5 mg
Number of subjects: 52
Study 11398305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray (both doses)
Number of subjects: 52
Study 11398305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11398305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray
Number of subjects: 52
Study 7880598 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Again rehabilitation programme
Number of subjects: 199
Study 7880598 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study 2464912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg per day for 4 weeks)
Number of subjects: 10
Study 2464912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 10
Study 2186673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms bid
Number of subjects: 99
Study 2186673 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo bid
Number of subjects: 99
Study 236737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication + parietal cell vagotomy (PCV)
Number of subjects: 29
Study 236737 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication alone
Number of subjects: 29
Study 31864178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (BREAK-2)
Number of subjects: 92
Study 31864178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (BREAK-3)
Number of subjects: 92
Study 31864178 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (BREAK-3)
Number of subjects: 92
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI grade 2
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI grade 3
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AFP ≥ 100 ng/ml
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tumor volume ≥ 250 cm3
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status 0–1
Number of subjects: 2186
Study 31659612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular invasion or metastasis
Number of subjects: 2186
Study 28496190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler (single maintenance and reliever therapy)
Number of subjects: 303
Study 28496190 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose budesonide/formoterol with salbutamol as reliever (Standard regimen)
Number of subjects: 303
Study 25888520 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based tele-supervising rehabilitation
Number of subjects: 210
Study 25888520 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 210
Study 22825926 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI)
Number of subjects: 70
Study 20728307 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of voice training
Number of subjects: 65
Study 20728307 — intervention group
Group type: COMPARATOR
Intervention: No voice training (Control)
Number of subjects: 65
Study 19367246 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) 3 times a week for 5 weeks
Number of subjects: 20
Study 19367246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MLD)
Number of subjects: 20
Study 17909141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene intervention from March 1, 1991, to May 31, 1992.
Number of subjects: 928
Study 17909141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hygiene intervention).
Number of subjects: 928
Study 17909141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene intervention.
Number of subjects: 928
Study 15531509 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human (rh) IGF‐I (20 microg/kg sc)
Number of subjects: 17
Study 15531509 — intervention group
Group type: COMPARATOR
Intervention: saline/rest, aerobic exercise, GHRH (1 microg/kg iv bolus), or GH‐releasing peptide‐2 (1 microg/kg iv bolus)
Number of subjects: 17
Study 11797116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonized autohemotransfusion
Number of subjects: 27
Study 11797116 — intervention group
Group type: COMPARATOR
Intervention: Non-ozonized autohemotransfusion (control)
Number of subjects: 27
Study 9797591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (intervention group)
Number of subjects: 230
Study 8054915 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2a at a dose of 1 x 10(6) units/day sc for 28 days with CYA
Number of subjects: 22
Study 8054915 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2a at a dose of 3 x 10(6) units/day sc for 28 days with CYA
Number of subjects: 22
Study 8054915 — intervention group
Group type: COMPARATOR
Intervention: CYA alone
Number of subjects: 22
Study 3281186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and para-aortic irradiation
Number of subjects: 441
Study 3281186 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation alone
Number of subjects: 441
Study 3281186 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aortic irradiation
Number of subjects: 441
Study 31434138 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic strength training with front-step exercise using a conical pulley, 2-3 sets of 6 repetitions each leg, during 9 weeks (CPG, n=10)
Number of subjects: 20
Study 31434138 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=10)
Number of subjects: 20
Study 28754796 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPT placebo arm
Number of subjects: 292
Study 28754796 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPT finasteride arm
Number of subjects: 292
Study 25910923 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 564
Study 25910923 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Immediate (ART-Immed)
Number of subjects: 564
Study 25910923 — intervention group
Group type: COMPARATOR
Intervention: ART-Deferred (ART-Def)
Number of subjects: 564
Study 22588852 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone with imipenem
Number of subjects: 29
Study 22588852 — intervention group
Group type: COMPARATOR
Intervention: Imipenem alone (Control)
Number of subjects: 29
Study 21414969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support (SMS)
Number of subjects: 54
Study 21414969 — intervention group
Group type: COMPARATOR
Intervention: Non-self-management support (non-SMS)
Number of subjects: 54
Study 19515371 — intervention group
Group type: COMPARATOR
Intervention: Drug conservation (DC)
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression (VS)
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HDL-p
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: Large HDL-p
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: Small HDL-p
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-p
Number of subjects: 728
Study 19515371 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-p
Number of subjects: 728
Study 16453980 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping
Number of subjects: 121
Study 16453980 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 121
Study 16453980 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping plus caffeine
Number of subjects: 121
Study 16453980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 16453980 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping plus caffeine (Field Study)
Number of subjects: 121
Study 16453980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Field Study)
Number of subjects: 121
Study 15022022 — intervention group
Group type: EXPERIMENTAL
Intervention: Thighs-flat position
Number of subjects: 20
Study 15022022 — intervention group
Group type: COMPARATOR
Intervention: Conventional lithotomy position
Number of subjects: 20
Study 15022022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar pad insertion
Number of subjects: 20
Study 11704584 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg budesonide
Number of subjects: 1970
Study 11704584 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg budesonide plus 4.5 microg formoterol
Number of subjects: 1970
Study 11704584 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide plus 4.5 microg formoterol
Number of subjects: 1970
Study 11704584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1970
Study 11704584 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide
Number of subjects: 1970
Study 9347001 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 49
Study 9347001 — intervention group
Group type: COMPARATOR
Intervention: Control (no NO)
Number of subjects: 49
Study 7643587 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional physical education (1 hour per day throughout primary schooling)
Number of subjects: 546
Study 7643587 — intervention group
Group type: COMPARATOR
Intervention: Control class-cohorts (preceding and succeeding classes)
Number of subjects: 546
Study 3038036 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre diet low in vasoactive amines
Number of subjects: 39
Study 3038036 — intervention group
Group type: COMPARATOR
Intervention: High fibre diet alone
Number of subjects: 39
Study 31882530 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 1105
Study 31882530 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 1105
Study 30125287 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-encoding emotion (neutral, positive, or negative video)
Number of subjects: 0
Study 27027634 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg grapiprant suspension
Number of subjects: 16
Study 27027634 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg grapiprant suspension
Number of subjects: 16
Study 27027634 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg grapiprant tablet
Number of subjects: 16
Study 27027634 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg grapiprant tablet
Number of subjects: 16
Study 25017614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0
Study 25017614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25017614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study 25017614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin and Placebo
Number of subjects: 0
Study 22399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the occipital cortex in the WM condition
Number of subjects: 0
Study 22399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the occipital cortex in the priming condition
Number of subjects: 0
Study 20100281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (15 pmol kg(‐1) min(‐1))
Number of subjects: 12
Study 20100281 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 19102593 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat cue (aversive white noise)
Number of subjects: 0
Study 19102593 — intervention group
Group type: COMPARATOR
Intervention: Control cue (neutral cue)
Number of subjects: 0
Study 16106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT) for 8 sessions over 8 weeks
Number of subjects: 27
Study 16106334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 11828293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g every 12 hours)
Number of subjects: 885
Study 11828293 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 g every 8 hours)
Number of subjects: 885
Study 11828293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 885
Study 11828293 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 885
Study 9895384 — intervention group
Group type: COMPARATOR
Intervention: Low dose amino acids (LDA)
Number of subjects: 8
Study 9895384 — intervention group
Group type: COMPARATOR
Intervention: High dose amino acids (HDA)
Number of subjects: 8
Study 7568441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein drink preload
Number of subjects: 0
Study 7568441 — intervention group
Group type: COMPARATOR
Intervention: High-protein drink preload
Number of subjects: 0
Study 7568441 — intervention group
Group type: COMPARATOR
Intervention: High-protein lunch
Number of subjects: 0
Study 7568441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein lunch
Number of subjects: 0
Study 2127017 — intervention group
Group type: EXPERIMENTAL
Intervention: External CO2 loading with controlled variations of inspiratory gas compositions aimed at a constant PetCO2 of 6.5 kPa (49 mm Hg) during moderate exercise.
Number of subjects: 0
Study 2127017 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise without external CO2 loading.
Number of subjects: 0
Study 153863 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day of Ro 10‐9359
Number of subjects: 30
Study 153863 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg twice every week of Ro 10‐9359
Number of subjects: 30
Study 31377456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone
Number of subjects: 100
Study 31377456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31553835 — intervention group
Group type: EXPERIMENTAL
Intervention: Quintupling the dose of fluticasone (to 250 μg twice a day)
Number of subjects: 0
Study 31553835 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the fluticasone (to 100 μg twice a day) and adding salmeterol (50 μg twice a day)
Number of subjects: 0
Study 31553835 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (low-dose fluticasone)
Number of subjects: 0
Study 31553835 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (medium-dose fluticasone)
Number of subjects: 0
Study 27858210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring-shaped thread counter traction ESD (RE)
Number of subjects: 45
Study 27858210 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD (CE)
Number of subjects: 45
Study 26945216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) with standard care
Number of subjects: 105
Study 26945216 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT) with standard care
Number of subjects: 105
Study 26945216 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 105
Study 24818541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-land strength group (LSG)
Number of subjects: 19
Study 24818541 — intervention group
Group type: EXPERIMENTAL
Intervention: In-water strength group (WSG)
Number of subjects: 19
Study 24818541 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 19
Study 22308084 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant LV leads (n=61)
Number of subjects: 85
Study 22308084 — intervention group
Group type: EXPERIMENTAL
Intervention: Long RV-LVs (≥82 ms)
Number of subjects: 85
Study 22308084 — intervention group
Group type: COMPARATOR
Intervention: RV lead positions (RV apex n=43, RV high posterior septum n=42)
Number of subjects: 85
Study 22308084 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors for reverse remodeling
Number of subjects: 85
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib(2.5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(10 µg)‐MenY(10 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0
Study 20697200 — intervention group
Group type: COMPARATOR
Intervention: Licensed conjugate MenC‐CRM197 vaccine co-administered with DTPa‐HBV‐IPV/Hib
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY and HibMenC conjugate vaccines
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY
Number of subjects: 0
Study 20697200 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 0
Study 18374301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% azithromycin in DuraSite
Number of subjects: 279
Study 18374301 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 279
Study 15649263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP, 200 microg/day)
Number of subjects: 0
Study 15649263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12420198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 27
Study 12420198 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 27
Study 10612505 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 31
Study 10612505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 31
Study 8546605 — intervention group
Group type: EXPERIMENTAL
Intervention: 750,000U of streptokinase (SK) in 15 min
Number of subjects: 110
Study 8546605 — intervention group
Group type: COMPARATOR
Intervention: 1.5 million U of streptokinase (SK) in 30 min
Number of subjects: 110
Study 1525095 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 444
Study 1525095 — intervention group
Group type: COMPARATOR
Intervention: Active policy (immediate oxytocin infusion)
Number of subjects: 444
Study 3839262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-prednisone (CP)
Number of subjects: 128
Study 3839262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, procarbazine and prednisone (COPP)
Number of subjects: 128
Study 3839262 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU, cyclophosphamide, vincristine, and prednisone (BCVP)
Number of subjects: 128
Study 3839262 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with periodic BCVP reinduction
Number of subjects: 128
Study 31155161 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSAIC treatment (two 60-minute home-based sessions and two 20-minute booster telephone calls incorporating behavior-change techniques)
Number of subjects: 24
Study 31155161 — intervention group
Group type: COMPARATOR
Intervention: Attention-control comparison
Number of subjects: 24
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced surveillance strategies (absenteeism monitoring in schools and cohort families with a toll-free number)
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 0 to 5 years
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 6 to 8 years
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 9 to 15 years
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Living conditions (sharing domestic space with other families)
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete protection with screens in doors and windows
Number of subjects: 1844
Study 30462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium and high risk areas
Number of subjects: 1844